Generic Pharmaceuticals Market To Reach $770.0 Billion By 2033

Generic Pharmaceuticals Market Growth & Trends

The global generic pharmaceuticals market is expected to reach over USD 770.0 billion by 2033, expanding at a CAGR of 6.5% from 2026 to 2033, according to a new study by Grand View Research Inc. The growth of the generic pharmaceuticals market is largely attributable to the expiry of product patents which clears the way for generic drugs and biosimilar manufacturers to launch products in the market. For instance, in July 2020, Teva Pharmaceutical Industries Ltd. entered into a joint venture with Takeda Pharmaceutical Company Limited aimed to manufacture and commercialize specialty assets, complex generic drugs, and other pipeline opportunities. This joint venture was anticipated to drive the generic pharmaceuticals market.

Furthermore, increasing government initiatives to promote generic drug products for reducing the overall healthcare expenditure on pharmaceuticals and the patent expiry of major products. For instance, the Therapeutic Goods Administration (TGA) Australia aims to offer affordable, efficient, high-quality, and accessible generic drugs to citizens for their treatment. In support of generic drugs, the TGA has been trying to reduce regulatory and reimbursement burdens such as changing the landscape of generic drugs and reducing barriers through international collaboration with manufacturers to launch their generic drugs in the market. Such initiatives of the Australian government open new avenues in the market.

In the U.S., every year millions of Americans use a generic drug for their treatment, hence, generic drugs remain the best bargain in the health care insurance programs, and given the recent enactment of healthcare reform legislation such as the introduction of the Patient Protection and Affordable Health Care Act. P.L. 111-148. Under this act, prescription drug coverage is mandated by the government as part of these new health insurance plans. The introduction of such policies may improve the quality and efficiency of healthcare, thereby, driving market growth.

The rising disease burden of infectious & non-infectious diseases coupled with the increasing geriatric population which is prone to chronic diseases such as diabetes, and hypertension, among others, may positively affect the market growth. According to an article published, in September 2022, around 17.9 million general population suffer from cardiovascular diseases (CVD) every year worldwide. Diseases including TB, diabetes, cardiovascular diseases, and HIV were among the major causes of death. The increasing incidence and prevalence of these diseases is expected to drive the market.

 Request a free sample copy or view report summary: Generic Pharmaceuticals Market Report

Generic Pharmaceuticals Market Report Highlights

• The simple generics segment led the market with the largest revenue share of 68.32% in 2025, due to its broad therapeutic relevance, high prescription volumes, and mature manufacturing and regulatory pathways.

• The cardiovascular disease segment led the market with the largest revenue share of 25.34% in 2025, driven by high clinical demand and patent expiries on key products.

• The small molecule segment led the market with the largest revenue share of 87.42% in 2025, due to its broad therapeutic applicability, mature regulatory pathways, and sustained reliance across chronic and acute disease management.

• The oral segment led the market with the largest revenue share of 73.62% in 2025, due to its clinical convenience, strong patient adherence, and entrenched role in chronic disease management.

• The retail pharmacies segment led the market with the largest revenue share of 51.88% in 2025, driven by its direct access to outpatient populations, high refill rates for chronic therapies, and its strong role in generic dispensing and substitution.

Generic Pharmaceuticals Market Segmentation

Grand View Research has segmented the global generic pharmaceuticals market on the basis of type, application, product, route of administration, distribution channel, and region:

Generic Pharmaceuticals Type Outlook (Revenue, USD Million, 2021 - 2033)

• Simple Generics

• Specialty Generics

• Biosimilars

Generic Pharmaceuticals Application Outlook (Revenue, USD Million, 2021 - 2033)

• Central Nervous System Disorders

• Respiratory Diseases

• Hormones and Related Diseases

• Gastrointestinal Diseases

• Cardiovascular Diseases

• Infectious Diseases

• Cancer

• Diabetes

• Others

Generic Pharmaceuticals Product Outlook (Revenue, USD Million, 2021 - 2033)

• Small Molecule

• Large Molecule

Generic Pharmaceuticals Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)

• Oral

• Injectable

• Inhalable

• Others

Generic Pharmaceuticals Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

• Online Pharmacies

• Retail Pharmacies

• Hospital Pharmacies

Generic Pharmaceuticals Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Generic Pharmaceuticals Market

• Teva Pharmaceutical Industries

• Sandoz

• Sun Pharmaceutical Industries

• Viatris

• Dr. Reddy’s Laboratories

• Cipla

• Aurobindo Pharma

• Lupin

• Glenmark Pharmaceuticals

• Torrent Pharmaceuticals